Guidance of Signaling Activations by Cadherins and Integrins in Epithelial Ovarian Cancer Cells

Epithelial ovarian cancer (EOC) is the deadliest tumor among gynecological cancer in the industrialized countries. The EOC incidence and mortality have remained unchanged over the last 30 years, despite the progress in diagnosis and treatment. In order to develop novel and more effective therapeutic approaches, the molecular mechanisms involved in EOC progression have been thoroughly investigated in the last few decades. At the late stage, peritoneal metastases originate from the attachment of small clusters of cancer cells that shed from the primary site and carried by the ascites adhere to the abdominal peritoneum or omentum. This behavior suggests that cell–cell or cell–matrix adhesion mechanisms regulate EOC growth and dissemination. Complex downstream signalings, which might be influenced by functional cross-talk between adhesion molecules and co-expressed and activated signaling proteins, can affect the proliferation/survival and the migration/invasion of EOC cells. This review aimed to define the impact of the mechanisms of cell–cell, through cadherins, and cell–extracellular matrix adhesion, through integrins, on the signaling cascades induced by membrane receptors and cytoplasmic proteins known to have a role in the proliferation, migration and invasion of EOC cells. Finally, some novel approaches using peptidomimetic ligands to cadherin and integrins are summarized.

[1]  M. Civera,et al.  Crystal Structure of Human E-Cadherin-EC1EC2 in Complex with a Peptidomimetic Competitive Inhibitor of Cadherin Homophilic Interaction. , 2016, Journal of medicinal chemistry.

[2]  J. Stebbing,et al.  Gene of the month: Axl , 2016, Journal of Clinical Pathology.

[3]  D. Arosio,et al.  Advancement in integrin facilitated drug delivery. , 2016, Advanced drug delivery reviews.

[4]  Stephen T. C. Wong,et al.  EMT is not required for lung metastasis but contributes to chemoresistance , 2015, Nature.

[5]  V. LeBleu,et al.  EMT Program is Dispensable for Metastasis but Induces Chemoresistance in Pancreatic Cancer , 2015, Nature.

[6]  E. Colvin,et al.  The Extracellular Matrix in Epithelial Ovarian Cancer – A Piece of a Puzzle , 2015, Front. Oncol..

[7]  V. Beral,et al.  Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer , 2015, Nature Reviews Cancer.

[8]  E. Burandt,et al.  E-Cadherin fragments as potential mediators for peritoneal metastasis in advanced epithelial ovarian cancer , 2015, British Journal of Cancer.

[9]  A. Tomassetti,et al.  Novel Axl-driven signaling pathway and molecular signature characterize high-grade ovarian cancer patients with poor clinical outcome , 2015, Oncotarget.

[10]  T. Regad Targeting RTK Signaling Pathways in Cancer , 2015, Cancers.

[11]  G. Samimi,et al.  INC280, an orally available small molecule inhibitor of c-MET, reduces migration and adhesion in ovarian cancer cell models , 2015, Scientific Reports.

[12]  Laura Belvisi,et al.  Cyclic isoDGR and RGD peptidomimetics containing bifunctional diketopiperazine scaffolds are integrin antagonists. , 2015, Chemistry.

[13]  N. Cordes,et al.  Focal adhesion signaling and therapy resistance in cancer. , 2015, Seminars in cancer biology.

[14]  D. Cheresh,et al.  Integrins and cancer: regulators of cancer stemness, metastasis, and drug resistance. , 2015, Trends in cell biology.

[15]  L. Monti,et al.  Pleiotropic modes of action in tumor cells of RNASET2, an evolutionary highly conserved extracellular RNase , 2015, Oncotarget.

[16]  M. Civera,et al.  Computational design of novel peptidomimetic inhibitors of cadherin homophilic interactions. , 2015, Organic & biomolecular chemistry.

[17]  O. Shoseyov,et al.  Human recombinant truncated RNASET2, devoid of RNase activity; A potential cancer therapeutic agent , 2014, Oncotarget.

[18]  J. George,et al.  Mesothelial cells promote early ovarian cancer metastasis through fibronectin secretion. , 2014, The Journal of clinical investigation.

[19]  K. Aldape,et al.  Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. , 2014, The Lancet. Oncology.

[20]  S. Tsao,et al.  p70 S6 kinase drives ovarian cancer metastasis through multicellular spheroid-peritoneum interaction and P-cadherin/β1 integrin signaling activation , 2014, Oncotarget.

[21]  Prahlad T. Ram,et al.  Hematogenous metastasis of ovarian cancer: rethinking mode of spread. , 2014, Cancer cell.

[22]  Xiuwen Wang,et al.  Construction and characteristics of an E-cadherin-related three-dimensional suspension growth model of ovarian cancer , 2014, Scientific Reports.

[23]  Gang Li,et al.  Downregulation of tumor suppressor gene ribonuclease T2 and gametogenetin binding protein 2 is associated with drug resistance in ovarian cancer. , 2014, Oncology reports.

[24]  S. Kellouche,et al.  Ascites-induced shift along epithelial-mesenchymal spectrum in ovarian cancer cells: enhancement of their invasive behavior partly dependant on αv integrins , 2014, Clinical & Experimental Metastasis.

[25]  Tuan Zea Tan,et al.  Epithelial–mesenchymal status renders differential responses to cisplatin in ovarian cancer , 2014, Oncogene.

[26]  M. Takeichi Dynamic contacts: rearranging adherens junctions to drive epithelial remodelling , 2014, Nature Reviews Molecular Cell Biology.

[27]  S. Ko,et al.  P-Cadherin Promotes Ovarian Cancer Dissemination Through Tumor Cell Aggregation and Tumor–Peritoneum Interactions , 2014, Molecular Cancer Research.

[28]  S. Kellouche,et al.  Cell cycle arrest or survival signaling through αv integrins, activation of PKC and ERK1/2 lead to anoikis resistance of ovarian cancer spheroids. , 2014, Experimental cell research.

[29]  N. Yousif Fibronectin promotes migration and invasion of ovarian cancer cells through up‐regulation of FAK–PI3K/Akt pathway , 2014, Cell biology international.

[30]  Yan Zhou,et al.  Effective Inhibition of c-MET-mediated Signaling, Growth, and Migration of Ovarian Cancer Cells is Influenced by the Ovarian Tissue Microenvironment , 2013, Oncogene.

[31]  Andrew J. Ewald,et al.  Collective Invasion in Breast Cancer Requires a Conserved Basal Epithelial Program , 2013, Cell.

[32]  N. Ahmed,et al.  Getting to Know Ovarian Cancer Ascites: Opportunities for Targeted Therapy-Based Translational Research , 2013, Front. Oncol..

[33]  D. Goldstein,et al.  Meta-Analysis of Microarray Data Identifies GAS6 Expression as an Independent Predictor of Poor Survival in Ovarian Cancer , 2013, BioMed research international.

[34]  L. Monti,et al.  Loss of function of Ribonuclease T2, an ancient and phylogenetically conserved RNase, plays a crucial role in ovarian tumorigenesis , 2013, Proceedings of the National Academy of Sciences.

[35]  A. Whittemore,et al.  Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studies. , 2013, International journal of epidemiology.

[36]  C. Lim,et al.  Tumor dissemination: an EMT affair. , 2013, Cancer cell.

[37]  S. Kaye,et al.  Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research , 2013, Nature Reviews Cancer.

[38]  Pei Wang,et al.  Antitumor Activity of Antimicrobial Peptides Containing CisoDGRC in CD13 Negative Breast Cancer Cells , 2013, PloS one.

[39]  L. Belvisi,et al.  Synthesis and biological evaluation (in vitro and in vivo) of cyclic arginine-glycine-aspartate (RGD) peptidomimetic-paclitaxel conjugates targeting integrin αVβ3. , 2012, Journal of medicinal chemistry.

[40]  Michael Peyton,et al.  An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance , 2012, Clinical Cancer Research.

[41]  K. Shen,et al.  The epidermal growth factor receptor as a therapeutic target in epithelial ovarian cancer. , 2012, Cancer epidemiology.

[42]  A. Tomassetti,et al.  Ligand-dependent EGFR activation induces the co-expression of IL-6 and PAI-1 via the NFkB pathway in advanced-stage epithelial ovarian cancer , 2012, Oncogene.

[43]  Andrew J Ewald,et al.  ECM microenvironment regulates collective migration and local dissemination in normal and malignant mammary epithelium , 2012, Proceedings of the National Academy of Sciences.

[44]  F. Vasile,et al.  Design, synthesis, and biological evaluation of novel cRGD-paclitaxel conjugates for integrin-assisted drug delivery. , 2012, Bioconjugate chemistry.

[45]  Jae Cheol Lee,et al.  Activation of the AXL Kinase Causes Resistance to EGFR-Targeted Therapy in Lung Cancer , 2012, Nature Genetics.

[46]  M. Civera,et al.  Synthesis of Gd and 68Ga Complexes in Conjugation with a Conformationally Optimized RGD Sequence as Potential MRI and PET Tumor‐Imaging Probes , 2012, ChemMedChem.

[47]  Shan Xu,et al.  E-cadherin promotes proliferation of human ovarian cancer cells in vitro via activating MEK/ERK pathway , 2012, Acta Pharmacologica Sinica.

[48]  V. Korshunov Axl-dependent signalling: a clinical update. , 2012, Clinical science.

[49]  E. Kohn,et al.  Adhesion molecule protein signature in ovarian cancer effusions is prognostic of patient outcome , 2012, Cancer.

[50]  O. Blaschuk Discovery and development of N-cadherin antagonists , 2012, Cell and Tissue Research.

[51]  K. Sawada,et al.  Integrin Inhibitors as a Therapeutic Agent for Ovarian Cancer , 2011, Journal of oncology.

[52]  Laura Belvisi,et al.  A new optical imaging probe targeting αVβ3 integrin in glioblastoma xenografts. , 2011, Contrast media & molecular imaging.

[53]  J. Heino,et al.  Cooperation between integrins and growth factor receptors in signaling and endocytosis. , 2011, Annual review of cell and developmental biology.

[54]  N. Bertos,et al.  Breast cancer - one term, many entities? , 2011, The Journal of clinical investigation.

[55]  Kenneth P. Nephew,et al.  Rethinking ovarian cancer: recommendations for improving outcomes , 2011, Nature Reviews Cancer.

[56]  W. Ou,et al.  Targeting HSP90 in ovarian cancers with multiple receptor tyrosine kinase coactivation , 2011, Molecular Cancer.

[57]  J. Guan,et al.  Focal adhesion kinase and its signaling pathways in cell migration and angiogenesis. , 2011, Advanced drug delivery reviews.

[58]  Gaudenz Danuser,et al.  Ovarian cancer spheroids use myosin-generated force to clear the mesothelium. , 2011, Cancer discovery.

[59]  P. Leung,et al.  P-cadherin cooperates with insulin-like growth factor-1 receptor to promote metastatic signaling of gonadotropin-releasing hormone in ovarian cancer via p120 catenin , 2011, Oncogene.

[60]  Hiroki Oda,et al.  Structural and functional diversity of cadherin at the adherens junction , 2011, The Journal of Cell Biology.

[61]  D. Armstrong,et al.  Recent progress in the diagnosis and treatment of ovarian cancer , 2011, CA: a cancer journal for clinicians.

[62]  Merrick I Ross,et al.  Prospective multicenter phase II trial of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with advanced extremity melanoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[64]  C. Desimone,et al.  Ten-Year Relative Survival for Epithelial Ovarian Cancer , 2011, Obstetrics and gynecology.

[65]  Jiri Bartek,et al.  Analysis of Epithelial and Mesenchymal Markers in Ovarian Cancer Reveals Phenotypic Heterogeneity and Plasticity , 2011, PloS one.

[66]  David A. Cheresh,et al.  Integrins in cancer: biological implications and therapeutic opportunities , 2010, Nature Reviews Cancer.

[67]  G. Daskalopoulos,et al.  Soluble adhesion molecules E-cadherin, intercellular adhesion molecule-1, and E-selectin as lung cancer biomarkers. , 2010, Chest.

[68]  E. Lengyel,et al.  Ligand independent activation of c-Met by fibronectin and α5β1-integrin regulates ovarian cancer invasion and metastasis , 2010, Oncogene.

[69]  Kevin Wei,et al.  AXL is an essential factor and therapeutic target for metastatic ovarian cancer. , 2010, Cancer research.

[70]  F. Carreiras,et al.  Mesothelial vitronectin stimulates migration of ovarian cancer cells , 2010, Cell biology international.

[71]  P. Leung,et al.  Cadherin switching and activation of p120 catenin signaling are mediators of gonadotropin-releasing hormone to promote tumor cell migration and invasion in ovarian cancer , 2010, Oncogene.

[72]  A. Sood,et al.  Combined anti-angiogenic therapy against VEGF and integrin alphabeta in an orthotopic model of ovarian cancer , 2009, Cancer biology & therapy.

[73]  M. Civera,et al.  Cyclic RGD‐Containing Functionalized Azabicycloalkane Peptides as Potent Integrin Antagonists for Tumor Targeting , 2009, ChemMedChem.

[74]  A. Mancuso,et al.  Clinical and pharmacological phase I evaluation of Exherin (ADH-1), a selective anti-N-cadherin peptide in patients with N-cadherin-expressing solid tumours. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[75]  G. Castellano,et al.  Variant HNF1 modulates epithelial plasticity of normal and transformed ovary cells. , 2008, Neoplasia.

[76]  Liz Y. Han,et al.  Tumor-selective response to antibody-mediated targeting of αvβ3 integrin in ovarian cancer , 2008 .

[77]  R. Tothill,et al.  Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome , 2008, Clinical Cancer Research.

[78]  Karen D. Cowden Dahl,et al.  Matrix metalloproteinase 9 is a mediator of epidermal growth factor-dependent e-cadherin loss in ovarian carcinoma cells. , 2008, Cancer research.

[79]  P. Febbo,et al.  Targeting N-cadherin enhances antitumor activity of cytotoxic therapies in melanoma treatment. , 2008, Cancer research.

[80]  F. Bussolino,et al.  Besides adhesion: new perspectives of integrin functions in angiogenesis. , 2008, Cardiovascular research.

[81]  E. Kistner,et al.  Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target. , 2008, Cancer research.

[82]  A. Baron,et al.  Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer. , 2008, Biochimica et biophysica acta.

[83]  Ie-Ming Shih,et al.  Pathogenesis of Ovarian Cancer: Lessons From Morphology and Molecular Biology and Their Clinical Implications , 2008, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[84]  W. Nelson,et al.  Localized zones of Rho and Rac activities drive initiation and expansion of epithelial cell–cell adhesion , 2007, The Journal of cell biology.

[85]  G. Rice,et al.  α2β1 integrin affects metastatic potential of ovarian carcinoma spheroids by supporting disaggregation and proteolysis , 2007, Journal of Carcinogenesis.

[86]  D. Fishman,et al.  Engagement of collagen-binding integrins promotes matrix metalloproteinase-9-dependent E-cadherin ectodomain shedding in ovarian carcinoma cells. , 2007, Cancer research.

[87]  A. Yap,et al.  Rac is a dominant regulator of cadherin-directed actin assembly that is activated by adhesive ligation independently of Tiam1. , 2007, American journal of physiology. Cell physiology.

[88]  E. Kistner,et al.  c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. , 2007, Cancer research.

[89]  O. Shoseyov,et al.  A recombinant human RNASET2 glycoprotein with antitumorigenic and antiangiogenic characteristics , 2006, Cancer.

[90]  R. Agarwal,et al.  Mechanisms of transcoelomic metastasis in ovarian cancer. , 2006, The Lancet. Oncology.

[91]  D. Schlaepfer,et al.  Integrin-regulated FAK-Src signaling in normal and cancer cells. , 2006, Current opinion in cell biology.

[92]  A. Citri,et al.  EGF–ERBB signalling: towards the systems level , 2006, Nature Reviews Molecular Cell Biology.

[93]  Yan Ning,et al.  Down-regulation of integrin alpha2 surface expression by mutant epidermal growth factor receptor (EGFRvIII) induces aberrant cell spreading and focal adhesion formation. , 2005, Cancer research.

[94]  H. Beug,et al.  Molecular requirements for epithelial-mesenchymal transition during tumor progression. , 2005, Current opinion in cell biology.

[95]  Yan Shen,et al.  Formation of E-cadherin-mediated cell-cell adhesion activates AKT and mitogen activated protein kinase via phosphatidylinositol 3 kinase and ligand-independent activation of epidermal growth factor receptor in ovarian cancer cells. , 2005, Molecular endocrinology.

[96]  J. Boyd,et al.  Gene Expression Profiles of Serous, Endometrioid, and Clear Cell Subtypes of Ovarian and Endometrial Cancer , 2005, Clinical Cancer Research.

[97]  B. de Strooper,et al.  ADAM10 mediates E-cadherin shedding and regulates epithelial cell-cell adhesion, migration, and beta-catenin translocation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[98]  A. Skubitz,et al.  Ovarian carcinoma spheroids disaggregate on type I collagen and invade live human mesothelial cell monolayers , 2005, Clinical & Experimental Metastasis.

[99]  L. Monti,et al.  Tumor and metastasis suppression by the human RNASET2 gene. , 2005, International journal of oncology.

[100]  A. Rustgi,et al.  No one-way street: Cross-talk between E-cadherin and receptor tyrosine kinase (RTK) signaling—A mechanism to regulate RTK activity , 2005, Cancer biology & therapy.

[101]  T. Shiozawa,et al.  Elevated expression of E-cadherin and α-, β-, and γ-catenins in metastatic lesions compared with primary epithelial ovarian carcinomas , 2004 .

[102]  T. Tamaya,et al.  Coexpression of Gas6/Axl in Human Ovarian Cancers , 2004, Oncology.

[103]  Ralph S Freedman,et al.  Peritoneal inflammation – A microenvironment for Epithelial Ovarian Cancer (EOC) , 2004, Journal of Translational Medicine.

[104]  L. Moro,et al.  Integrin regulation of epidermal growth factor (EGF) receptor and of EGF-dependent responses. , 2004, Biochemical Society transactions.

[105]  Kenneth J. Hillan,et al.  Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer , 2004, Nature Reviews Drug Discovery.

[106]  Douglas R Lowy,et al.  E‐cadherin‐mediated adhesion inhibits ligand‐dependent activation of diverse receptor tyrosine kinases , 2004, The EMBO journal.

[107]  Albert B. Reynolds,et al.  A core function for p120-catenin in cadherin turnover , 2003, The Journal of cell biology.

[108]  Keith R. Johnson,et al.  Cadherin-mediated cellular signaling. , 2003, Current opinion in cell biology.

[109]  K. Münstedt,et al.  Association between fibronectin expression and prognosis in ovarian carcinoma. , 2003, Anticancer research.

[110]  C. Maccalman,et al.  Cadherin switching in ovarian cancer progression , 2003, International journal of cancer.

[111]  B. Gumbiner,et al.  Adhesion-independent mechanism for suppression of tumor cell invasion by E-cadherin , 2003, The Journal of cell biology.

[112]  E. van Marck,et al.  Inflammatory breast cancer shows angiogenesis with high endothelial proliferation rate and strong E-cadherin expression , 2003, British Journal of Cancer.

[113]  G. Nemerow,et al.  Differential regulation of cell motility and invasion by FAK , 2003, The Journal of cell biology.

[114]  G. Serban,et al.  A presenilin‐1/γ‐secretase cleavage releases the E‐cadherin intracellular domain and regulates disassembly of adherens junctions , 2002, The EMBO journal.

[115]  T. P. Pretlow,et al.  Aberrant P-cadherin expression is an early event in hyperplastic and dysplastic transformation in the colon , 2002, Gut.

[116]  C. Tacchetti,et al.  Integrin-induced Epidermal Growth Factor (EGF) Receptor Activation Requires c-Src and p130Cas and Leads to Phosphorylation of Specific EGF Receptor Tyrosines* , 2002, The Journal of Biological Chemistry.

[117]  E. Kovacs,et al.  E-cadherin Homophilic Ligation Directly Signals through Rac and Phosphatidylinositol 3-Kinase to Regulate Adhesive Contacts* , 2002, The Journal of Biological Chemistry.

[118]  G. Rice,et al.  Overexpression of αvβ6 integrin in serous epithelial ovarian cancer regulates extracellular matrix degradation via the plasminogen activation cascade , 2002 .

[119]  Kozo Kaibuchi,et al.  Rho-family GTPases in cadherin-mediated cell — cell adhesion , 2001, Nature Reviews Molecular Cell Biology.

[120]  F. Giancotti,et al.  EGF-R signaling through Fyn kinase disrupts the function of integrin α6β4 at hemidesmosomes , 2001, The Journal of Cell Biology.

[121]  N. Hacker,et al.  Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells. , 2001, Journal of the National Cancer Institute.

[122]  P. Comoglio,et al.  Pathway specificity for Met signalling , 2001, Nature Cell Biology.

[123]  K. Kaibuchi,et al.  Recruitment and activation of Rac1 by the formation of E-cadherin-mediated cell-cell adhesion sites. , 2001, Journal of cell science.

[124]  David I. Smith,et al.  Cloning and characterization of a senescence inducing and class II tumor suppressor gene in ovarian carcinoma at chromosome region 6q27 , 2001, Oncogene.

[125]  D. Sacks,et al.  E-cadherin-mediated Cell-Cell Attachment Activates Cdc42* , 2000, The Journal of Biological Chemistry.

[126]  A. P. Soler,et al.  P‐cadherin expression in breast carcinoma indicates poor survival , 1999, Cancer.

[127]  G. Fleuren,et al.  Changing roles of cadherins and catenins during progression of squamous intraepithelial lesions in the uterine cervix. , 1999, The American journal of pathology.

[128]  Horst Kessler,et al.  N-methylated cyclic RGD peptides as highly active and selective αvβ3 integrin antagonists , 1999 .

[129]  L. Silengo,et al.  Integrins induce activation of EGF receptor: role in MAP kinase induction and adhesion‐dependent cell survival , 1998, The EMBO journal.

[130]  E. Ruoslahti,et al.  Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. , 1998, Science.

[131]  Worsley,et al.  Expression of E‐cadherin, α‐catenin and β‐catenin in normal ovarian surface epithelium and epithelial ovarian cancers , 1998 .

[132]  J. Scoazec,et al.  Expression of cadherins in benign, borderline, and malignant ovarian epithelial tumors: a clinicopathologic study of 60 cases. , 1997, Human pathology.

[133]  S. Enerbäck,et al.  E‐cadherin expression in human epithelial ovarian cancer and normal ovary , 1997, International journal of cancer.

[134]  H. Fujiwara,et al.  Inhibition of Growth and Metastasis of Ovarian Carcinoma by Administering a Drug Capable of Interfering with Vascular Endothelial Growth Factor Activity , 1996, Japanese journal of cancer research : Gann.

[135]  Peter D. Kwong,et al.  Structural basis of cell-cell adhesion by cadherins , 1995, Nature.

[136]  T. Hunter,et al.  Integrin-mediated signal transduction linked to Ras pathway by GRB2 binding to focal adhesion kinase , 1994, Nature.

[137]  S. Orsulic,et al.  Ovarian Cancer , 1993, British Journal of Cancer.

[138]  D. Wheatley,et al.  AN ELECTRON MICROSCOPIC STUDY OF THE INVASION OF ASCITES TUMOR CELLS INTO THE ABDOMINAL WALL. , 1965, Cancer research.

[139]  M. Dewhirst,et al.  Targeting N-cadherin increases vascular permeability and differentially activates AKT in melanoma. , 2015, Annals of surgery.

[140]  Alexander Gheldof,et al.  Cadherins and epithelial-to-mesenchymal transition. , 2013, Progress in molecular biology and translational science.

[141]  P. Leung,et al.  Targeting gonadotropin-releasing hormone receptor inhibits the early step of ovarian cancer metastasis by modulating tumor-mesothelial adhesion. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[142]  J. Blaakaer,et al.  The association between endometriosis and ovarian cancer: a review of histological, genetic and molecular alterations. , 2012, Gynecologic oncology.

[143]  K. Brown,et al.  Synthesis and Biological Evaluation of a Peptide Paclitaxel Conjugate Which Targets the Integrin α v β 6 , 2011 .

[144]  M. Stack,et al.  Microenvironmental regulation of ovarian cancer metastasis. , 2009, Cancer treatment and research.

[145]  M. Hollingsworth,et al.  ADH‐1 suppresses N‐cadherin‐dependent pancreatic cancer progression , 2008, International journal of cancer.

[146]  H. Earp,et al.  TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer. , 2008, Advances in cancer research.

[147]  B. Strooper,et al.  ADAM 10 mediates E-cadherin shedding and regulates epithelial cell – cell adhesion , migration , and-catenin translocation , 2005 .

[148]  M. Mareel,et al.  Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. , 2001, Journal of cell science.

[149]  H. Barr,et al.  Altered cadherin and catenin complexes in the Barrett's esophagus-dysplasia-adenocarcinoma sequence: correlation with disease progression and dedifferentiation. , 1998, The American journal of pathology.

[150]  H. Sakahara,et al.  Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels. , 1997, British Journal of Cancer.

[151]  E Ruoslahti,et al.  RGD and other recognition sequences for integrins. , 1996, Annual review of cell and developmental biology.